CX3CL1

Gene Synonyms:

Protein Names:

Organism:

Homo sapiens (Human)

Mass (kDa):

42203

Length (aa):

397

Sequence:

MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIPVALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGTFEKQIGEVKPRTTPAAGGMDESVVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTGVTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEAPSTQDPSTQASTASSPAPEENAPSEGQRVWGQGQSPRPENSLEREEMGPVPAHTDAFQDWGPGSMAHVSVVPVSSEGTPSREPVASGSWTPKAEEPIHATMDPQRLGVLITPVPDAQAATRRQAVGLLAFLGLLFCLGVAMFTYQSLQGCPRKMAGEMAEGLRYIPRSCGSNSYVLVPV

Proteomics (Proteome ID):

Fractalkine (C-X3-C motif chemokine 1) (CX3C membrane-anchored chemokine) (Neurotactin) (Small-inducible cytokine D1) [Cleaved into: Processed fractalkine]

Proteomics (Chromosome):

UP000005640

Mass Spectrometry:

N/A

Function [CC]:

Acts as a ligand for both CX3CR1 and integrins. Binds to CX3CR1 (PubMed:23125415, PubMed:9931005, PubMed:21829356). Binds to integrins ITGAV:ITGB3 and ITGA4:ITGB1. Can activate integrins in both a CX3CR1-dependent and CX3CR1-independent manner. In the presence of CX3CR1, activates integrins by binding to the classical ligand-binding site (site 1) in integrins. In the absence of CX3CR1, binds to a second site (site 2) in integrins which is distinct from site 1 and enhances the binding of other integrin ligands to site 1 (PubMed:23125415, PubMed:24789099). The soluble form is chemotactic for T-cells and monocytes and not for neutrophils. The membrane-bound form promotes adhesion of those leukocytes to endothelial cells. May play a role in regulating leukocyte adhesion and migration processes at the endothelium (PubMed:9024663, PubMed:9177350). {ECO:0000269|PubMed:21829356, ECO:0000269|PubMed:23125415, ECO:0000269|PubMed:24789099, ECO:0000269|PubMed:9024663, ECO:0000269|PubMed:9177350, ECO:0000269|PubMed:9931005}.

Metal Binding:

N/A

Site:

SITE 339 340 Cleavage; to produce soluble form. {ECO:0000255}.

Tissue Specificity:

Expressed in the seminal plasma, endometrial fluid and follicular fluid (at protein level). Small intestine, colon, testis, prostate, heart, brain, lung, skeletal muscle, kidney and pancreas. Most abundant in the brain and heart. {ECO:0000269|PubMed:23765988, ECO:0000269|PubMed:9024663, ECO:0000269|PubMed:9177350}.

Disease:

N/A

Mutagenesis:

MUTAGEN 60 60 K->A: Reduced binding to integrin ITGAV:ITGB3, but no effect on binding to CX3CR1; when associated with A-61. {ECO:0000269|PubMed:23125415}.; MUTAGEN 60 60 K->E: Dominant-negative mutant, reduced binding to integrins ITGAV:ITGB3 and ITGA4:ITGB1, no effect on binding to CX3CR1, defective in ternary complex formation, integrin activation and fractalkine signaling and suppression of leukocyte recruitment in the peritonitis model in vivo; when associated with E-61. {ECO:0000269|PubMed:23125415, ECO:0000269|PubMed:24789099}.; MUTAGEN 61 61 R->A: Reduced binding to integrin ITGAV:ITGB3, but no effect on binding to CX3CR1; when associated with A-60. {ECO:0000269|PubMed:23125415}.; MUTAGEN 61 61 R->E: Dominant-negative mutant, reduced binding to integrins ITGAV:ITGB3 and ITGA4:ITGB1, no effect on binding to CX3CR1, defective in ternary complex formation, integrin activation and fractalkine signaling and suppression of leukocyte recruitment in the peritonitis model in vivo; when associated with E-60. {ECO:0000269|PubMed:23125415, ECO:0000269|PubMed:24789099}.; MUTAGEN 71 71 R->A: Loss of binding to CX3CR1 and ability to induce chemotaxis but no effect on binding to integrins. {ECO:0000269|PubMed:23125415}.; MUTAGEN 78 78 K->A: Little or no effect on binding to integrin ITGAV:ITGB3. {ECO:0000269|PubMed:23125415}.; MUTAGEN 78 78 K->A: Little or no effect on binding to integrin ITGAV:ITGB3; when associated with A-83. {ECO:0000269|PubMed:23125415}.; MUTAGEN 83 83 K->A: Little or no effect on binding to integrin ITGAV:ITGB3; when associated with A-78. {ECO:0000269|PubMed:23125415}.

Name:

Fractalkine (C-X3-C motif chemokine 1) (CX3C membrane-anchored chemokine) (Neurotactin) (Small-inducible cytokine D1) [Cleaved into: Processed fractalkine]

Class:

Subcategory:

Recombinant

Source:

Species:

Human

Amino Acid Sequence:

Tag:

Format:

Lyophilized

Formulation:

Sterile-filtered colorless solution

Formulation Concentration:

1mg/ml

Buffer Volume:

Standard

Buffer Solution:

PBS

pH:

7.4-7.5

NaCl:

Null

EDTA:

Null

Purity:

> 98%

Determined:

SDS-PAGE

Stained:

Inquire

Validated:

RP-HPLC

Storage:

-20°C

Stability:

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Preparation:

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.